Estimated Total Annual Burden Hours: 125

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: *infocollection@acf.hhs.gov.* 

*OMB Comment:* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, *Fax:* 202–395–6974, *Attn:* Desk Officer for the Administration for Children and Families.

Dated: June 18, 2008.

Janean Chambers,

Reports Clearance Officer.

[FR Doc. E8–14161 Filed 6–25–08; 8:45 am] BILLING CODE 4184–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Administration for Children and Families

#### Office of Refugee Resettlement; Unaccompanied Alien Children Shelter Care Facilities

**AGENCY:** Office of Refugee Resettlement, ACF, DHHS.

**ACTION:** Notice to award ten noncompetitive supplements to existing Unaccompanied Alien Children (UAC) Shelter Care Facilities.

#### CFDA #: 93.676.

*Legslative Authority:* The Office of Refugee Resettlement (ORR) is mandated by Section 462 of the Homeland Security Act to ensure appropriate placement of all unaccompanied alien children referred to ORR for care and custody by the Department of Homeland Security (DHS).

Amount of Award: \$2,521,320. **SUMMARY:** This notice announces that the Administration for Children and Families (ACF), Office of Refugee Resettlement intends to award ten unaccompanied alien shelter care providers in the amount of \$2,521,320. This funding will support services through September 30, 2008.

Grantee	Location	Project period	Amount	
Southwest Key—El Paso	El Paso, TX	06/10/08-09/30/08	\$390,320	
The Children's Village	New York, NY	06/10/08-09/30/08	445,000	
Florence Crittenton	Los Angeles, CA	06/10/08-09/30/08	336,000	
Lutheran Social Services of the South	Austin, TX	06/10/08-09/30/08	600,000	
Heartland/ICC	Chicago, IL	06/10/08-09/30/08	325,000	
Southwest Indiana Youth Village	Vincennes, IN	06/10/08-09/30/08	120,000	
International Educational Services—Foster Care.	Brownsville, TX	06/10/08-09/30/08	90,000	
International Educational Services—Foster Care.	Harlingen, TX	06/10/08-09/30/08	70,000	
Pioneer Services	Fife, WA	06/10/08-09/30/08	85,000	
Southwest Key—Pleasant Hill	Pleasant Hill, CA	06/10/08-09/30/08	60,000	

This funding will support the expansion of shelter/foster/staff secure/ secured/therapeutic care program bed capacity to meet the number of unaccompanied alien children referrals from the Department of Homeland Security (DHS). This expansion is necessary to replace bed capacity discontinued at several sites as well as to accommodate the increase of length of stay of UAC in ORR's care. This supplemental funding will support the additional bed capacity through the summer high season, terminating at the end of the 2008 fiscal year.

To ensure the program would have complete flexibility to expand and contract to meet the ever-changing demands of the program, ORR specifically included language in its program announcement to stipulate that funding and capacity may increase based on the needs of the program. The program has very specific requirements for the provision of services. Existing grantees are the only entities with the infrastructure, licensing, experience and appropriate level of trained staff to meet the service requirements and the urgent need for expansion. The program's ability to avoid a backlog of children waiting in border patrol stations for placement can only be accommodated through the expansion of existing programs through this supplemental award process.

# FOR FURTHER INFORMATION CONTACT:

Kenneth Tota, Office of Refugee Resettlement, Administration for Children and Families, 370 L'Enfant Promenade, SW., Washington, DC 20447, telephone (202) 401–4858.

Dated: June 17, 2008.

## David H. Siegel,

Acting Director, Office of Refugee Resettlement. [FR Doc. E8–14429 Filed 6–25–08; 8:45 am] BILLING CODE 4184–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. FDA-2008-N-0173]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Appeals of Science-Based Decisions Above the Division Level at the Center for Veterinary Medicine

**AGENCY:** Food and Drug Administration, HHS.

# ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by July 28, 2008.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–6974, or e-mailed to *baguilar@omb.eop.gov*. All comments should be identified with the OMB control number 0910–0566. Also include the FDA docket number found in brackets in the heading of this document.

## FOR FURTHER INFORMATION CONTACT:

Denver Presley, Jr., Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 1472.

#### SUPPLEMENTARY INFORMATION: In

compliance with 44 U.S.C. 3507, FDA has submitted the following proposed

collection of information to OMB for review and clearance.

## Appeals of Science-Based Decisions Above the Division Level at the Center for Veterinary Medicine (OMB Control Number 0910–0566)—Extension

CVM's (Center for Veterinary Medicine) "Guidance for Industry #79-Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by the Center for Veterinary Medicine" describes the process by which CVM formally resolves disputes relating to scientific controversies. A scientific controversy involves issues concerning a specific product regulated by CVM related to matters of technical expertise and requires specialized education, training or experience to be understood and resolved. Further, the guidance details information on how the agency intends to interpret and apply provisions of the existing regulations

regarding internal agency review of decisions. In addition, the guidance outlines the established recommended procedures for persons who are applicants, including sponsor applicants or manufacturers, for animal drugs or other products regulated by CVM, that wish to submit a request for review of a scientific dispute. When an applicant has a scientific disagreement and a written decision by CVM, the applicant may submit a request for review of that decision by following the established agency channels of supervision for review.

Respondents to this collection of information are applicants that wish to submit a request for review of a scientific dispute.

In the **Federal Register** of March 26, 2008 (73 FR 16021), FDA published a 60-day notice requesting public comment on the information collection provisions. No comments were received.

#### TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN<sup>1</sup>

21 CFR section	No. of respondents	Annual frequency per response	Total annual responses	Hours per response	Total hours
10.75	2	4	8	10	80

There are no capital costs or operating and maintenance costs associated with this collection of information.

This estimated annual reporting burden is based on CVM's experience over the past 3 years in handling formal appeals for scientific disputes. The number of respondents multiplied by the annual frequency of response equals the total annual responses. The number of hours per response is based on discussions with industry and may vary depending on the complexity of the issue(s) involved and the duration of the appeal process.

Dated: June 19, 2008.

## Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–14515 Filed 6–25–08; 8:45 am] BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

## Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

# ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee

of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee*: Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee.

*General Function of the Committee*: To provide advice and recommendations to the agency on

FDA's regulatory issues.

Date and Time: The meeting will be held on July 18, 2008, from 8 a.m. to 5 p.m.

*Location*: Hilton Washington DC North/Gaithersburg, Salons A, B, and C, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Louise E. Magruder, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 240-276-1248, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512515. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal **Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn

about possible modifications before coming to the meeting.

Agenda: The committee will discuss and make recommendations on issues relevant to the potential for automated differential cell counters being waived under the Clinical Laboratory Improvement Amendments of 1988. The discussion will include pre-analytical, analytical, and post-analytical issues associated with performing automated hematology complete blood counts and differentials in a waived setting. (See www.fda.gov/cdrh/oivd/guidance/ 1171.html).

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at *http://www.fda.gov/ohrms/ dockets/ac/acmenu.htm*, click on the year 2008 and scroll down to the appropriate advisory committee link.

*Procedure*: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact